Monoclonal antibody inhibitor of factor XIIA
US10913802B2 · kind B2 · utility
3Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 21, 2016 |
| Grant date | Feb 9, 2021 |
| Priority date | — |
| Expiry date | Jan 5, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.